Ignite Creation Date:
2024-05-06 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05167409
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2021-09-27
Brief Title:
A Study of Evorpacept ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Sponsor:
University of Colorado Denver
Organization:
University of Colorado Denver
Organization Data
Organization:
University of Colorado Denver
Class:
OTHER
Study ID:
22-0110cc
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of Colorado Denver
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| ALX Oncology Inc | INDUSTRY |
| Merck Sharp Dohme LLC | INDUSTRY |
| Eli Lilly and Company | INDUSTRY |
| Criterium Inc | INDUSTRY |
| Academic GI Cancer Consortium AGICC | OTHER |